Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

NCT06052839 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Interventions

DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Dan Zandberg